CellGenix expands HQ to meet increasing demand for GMP cell culture reagents

Published: 23-Feb-2017

Strong growth in cell and gene therapy is leading to increased demand for GMP-grade raw materials such as cytokines and serum-free media


CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, has started facility expansions as more customers approach late-stage clinical development and commercialisation.

Early in 2018, the company will add R&D laboratory, production and warehouse space to its German HQ in Freiburg, Germany.

Consequently, there will be new positions in R&D as well as QC and production to fill. The upgrade also introduces state-of-the-art, large scale, filling capacities for recombinant protein products in the existing GMP facilities.

The market forecasts strong growth in cell and gene therapy leading to increased demand for GMP-grade raw materials.

“The investment we are making is a very positive sign for the gene and cell therapy space and the future of CellGenix. It will allow us to fulfill the increasing demand for GMP-grade cytokines and serum-free media. It also shows the importance of high quality GMP reagents for safe, reliable and successful cell and gene therapy manufacturing.” says Prof. Dr Felicia Rosenthal, CEO of CellGenix.

Trending Articles

You may also like